118 results about "Immunosuppressive drug" patented technology

Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

The intervertebral disc is avascular. With aging, endplates become occluded by calcified layers, and diffusion of nutrients and oxygen into the disc diminishes. The disc degenerates, and pain ensues. Conduits are delivered and deployed into the intervertebral disc to reestablish the exchange of nutrients and waste between the disc and bodily circulation to stop or reverse disc degeneration and relieve pain. The intervertebral disc installed with semi-permeable conduits may be used as an immuno-isolated capsule to encapsulate donor cells capable of biosynthesizing therapeutic molecules. The semi-permeable conduits establish the exchange of nutrients and therapeutic molecules between disc and bodily circulation to treat a disease without using immunosuppressive drugs.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

The invention relates to a method for differentially hemolyzing whole blood. It discloses method for detecting an analyte in a liquid sample known or suspected to comprise red blood cells and suspected or known to comprise eukaryotic cells, the method comprising the steps of processing said liquid sample with a membrane solubilizing agent under conditions appropriate to lyse cell membranes of red blood cells and at the same time not to cause precipitation of sample constituents, subjecting the processed sample to a chromatographic separation, and detecting the analyte. The differential hemolysis of red blood cells is of advantage in a method of detecting an analyte in a liquid sample that may comprise both erythrocytes as well as nucleated cells. The differential solubilization of red blood cells can be easily combined with an online detection methodology, like LC-MS, and is advantageous in the detection of many analytes, e.g. in the detection of folate or of immunosuppressive drugs, like tacrolimus or sirolimus.

The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

This invention is in the field of a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor, a 5-lipoxygenase inhibitor and an immunosuppressive drug selected from antiproliferative agents, antiinflammatory-acting compounds and inhibitors of leukocyte activation. This combination may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

An implantable medical device such as a catheter includes an outer controlled-release layer with a pharmacologically active ingredient for helping to prevent the occurrence or recurrence of cancer, or an immunosuppressive drug. The outer layer includes a bioactive material such as paclitaxel or other drug known to help reduce the incidence of formation of tumors or other cancerous items within the body of a patient.

A method of treating a subject in need of a cell or tissue transplant is disclosed. The method comprising (a) transplanting a non-syngeneic cell or tissue transplant into the subject, wherein the transplant comprises bone marrow or lymphoid cells; and (b) administering to the subject a therapeutically effective amount of an immunosuppressive regimen comprising a Sphingosine 1-Phosphate Receptor Agonist, a B7 molecule inhibitor and a CD2 / CD58 pathway inhibitor, thereby treating the subject.

The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE2 or TGF-β1 comprising the step of culturing NOD2-expressing stem cells in culture medium with a NOD2 agonist, a graft comprising stem cells expressing NOD2 and the NOD2 agonist, a method for preparing the graft, a composite comprising stem cells expressing NOD2 and the NOD2 agonist, and a culture generated by culturing the NOD2-expressing stem cells with a NOD2 agonist.

The invention relates to an amino methanol derivant and a salt compound thereof as well as a synthesizing method and medical application thereof, belonging to the field of medicines. The medical application is applied in preparing immunosuppressive drugs and drugs for treating transplant rejection, immune and inflammatory diseases, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. The amino methanol derivant and a physiological salt thereof only act on S1P1, downwards regulate the S1P1 expression and suppress lymphocytes from entering peripheral blood circulation.

The invention discloses an accurate prediction method for a tacrolimus dosage of an organ transplantation patient. The method comprises the following steps: collecting model establishment data including but not limited to patient personal data, tacrolimus clinical medication data based on the organ transplantation patient and gene detection data; carrying out management and statistical analysis on the collected model establishment data; and establishing a tacrolimus dosage model for organ transplantation based on the model establishment data, wherein the model establishment comprises data arrangement, basic structure model, covariable incorporation and model verification. The tacrolimus accurate dosage prediction mathematical model helps clinically and accurately predict the initial medication dosage and dosage adjustment scheme of an individual patient, reduces toxic and side effects caused by too large tacrolimus dosage or the risk of rejection caused by too low tacrolimus dosage of the patient, reduces the occurrence rate of acute rejection reaction and reduces adverse drug events. The prediction method has important significance on accurate application of immunosuppressive drugs for organ transplantation patients; meanwhile, has good economic benefits and social benefits.

The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

The invention relates to a novel substituted benzoyl urea compound and a preparation method and application thereof. The compound has the structure general formula disclosed in (I), wherein definitions of R1, R2, and R3 are described in the specification, and the compound can be used as a micromolecule inhibitor of Cyclophilin A (CypA); the CypA is a protein with the activity of Peptidyl-prolyl cis-trans isomerase (PPIase), and is related to the in vivo protein folding, assembly and transfer. The current research shows that the CrpA takes part in various physiology approaches, such as autoimmunity depression, HIV-1 invasion infection and the like. Therefore, the compound of the invention can become a novel immunosuppressive drug or anti-HIV-1 drug.

Use of an immunomodulatory, immunostimulatory, or immunosuppressive drug in the manufacture of a medicament for treatment of a skin related disease or disorder, wherein the drug is formulated for topical administration to porated skin having a plurality of pores with predetermined geometry such that the concentration of the drug in combination with the predetermined geometry of the pores are effective in treatment of the skin related disease or disorder. The method of facilitating treatment of a skin related disease or disorder, comprising providing information that a drug is effective in treatment of the skin related disease or disorder; providing information to apply the drug to an area of porated skin comprising a plurality of pores; wherein the information specifies that the area is equal or greater than 1 cm2; wherein the information further specifies that at least some of the plurality of pores have a predetermined geometry; and wherein the predetermined geometry is effective to substantially prevent systemic administration of the drug.

Methods for the diagnosis and treatment of fungal infections caused by microorganisms producing glucosylceramide are provided. In particular, methods for diagnosing or predicting dissemination of a fungal infection from the lungs to the blood stream of a patient are provided. Methods for treating a fungal infection and / or preventing the dissemination of a fungal infection from the lungs to the blood stream or to other organs of a patient, and methods for preventing or treating a fungal infection in a patient by administering a therapeutically effective amount of a fungal glucosylceramide synthase inhibitor to a patient. Such methods are particularly useful for use with patients at risk to develop fungal infections, such as HIV or cancer patients, patients hospitalized in intensive care units, or patients receiving immunosuppressive drugs such as transplant patients.

Methods for monitoring the immune response and predicting clinical outcomes for patients on immunosuppressive drugs (such as transplant patients) are provided. The methods are based on the measurement of an intracellular metabolic marker in lymphocytes (such as ATP) as an indicator of a patient's immune response.

The invention discloses an ephedra total polysaccharide extractive and a preparation method and a medical application thereof. The ephedra total polysaccharide in the invention is acid total polysaccharide, calculated by glucose, and the weight percent content of the acid total polysaccharide accounts for 45% or over 45% of the total weight of ephedra total polysaccharide extractive. In the invention, a large number of pharmacological experiments discover that the ephedra acid total polysaccharide extractive has prominent immunosuppressive activity, has no toxic and side effects, can be prepared to drugs used as immunosuppressant or can be used as bulk drug for preparing other immunosuppressive drugs, and can be used for curing various diseases related to over-immunity, comprising allergic asthma, chronic nephritis, rheumatoid arthritis, systemic lupus erythematosus, body rejection caused by organ transplantation and other diseases related to over-immunity.

The invention belongs to the technical field of biology, relates to preparation of bionic nano-carriers and targeted treatment of arthritis, and particularly relates to a macrophage vesicle entrappednano-drug preparation and application thereof in treating arthritis. The nano-drug preparation targets an arthritis part through adhesive protein on the surface of a macrophage vesicle, and an immunosuppressive drug is delivered for targeted treatment of arthritis. Furthermore, a new strategy for targeted treatment of arthritis is provided for clinical practice, and the strategy comprises the steps of fusing an artificial drug carrier and the natural macrophage vesicle, and constructing the stable macrophage vesicle entrapped nano-drug preparation, thereby improving the targeted treatment effect of arthritis.

The invention belongs to the field of traditional Chinese medicine and relates to a total cedar polysaccharide. The polysaccharide is a water-soluble crude polysaccharide extracted and prepared from Sabina pingii var.wilsonii branches and leaves, and the structural characteristics such as sugar content, uronic acid content, protein content, molecular weight distribution and monosaccharide composition of the polysaccharide are represented. Activity determination results indicate that the cedar polysaccharide has an obvious anticomplementary action, the half effective inhibition concentration of a complement activation classical pathway is up to 23-35 micro-g / ml, and the polysaccharide is equivalent to a positive control drug in heparin sodium activity. In addition, the level of mouse peritoneal macrophage cell secretion NO under LPS stimulation can be remarkably inhibited, and it is indicated that the total cedar polysaccharide has a very good anti-inflammatory effect. The total cedar polysaccharide can be used for preparing anti-complement, anti-inflammatory and other immunosuppressive related drugs.

Methods for inducing tolerance to a transplant in a subject are disclosed. The methods comprise administering multiple doses of a therapeutically effective amount of a CD40 antagonist alone or in combination with a CD86 antagonist, wherein the first dose of the antagonist is given before or at the time of transplantation; and administering multiple doses of a therapeutically effective amount of an immunosuppressive drug, wherein the first dose of the immunosuppressive drug is given at least several days after transplantation.

The present invention provides a simple, economical yet efficient method of creating transplant tolerance in organ transplant patients without the continuous need for costly immunosuppressive drugs with serious adverse effects. The invention essentially deals with the administration of a novel composition to the patient which consists of adipose tissue derived Mesenchymal Stem Cells (MSC) combined with bone marrow derived Haematopoietic Stem Cells(HSC) and MSC and peripheral blood stem cells (PBSC). This helps in creating transplant tolerance ie. Stable adequate allograft function with minimum / no rejection using very low dose of immunosuppressive medication. The invention also deals with a simple method of isolating Mesenchymal Stem cells from human adipose tissue without using any xenogenic material.

A tacrolimus slow-release mini-pill and a preparation method thereof are disclosed, the tacrolimus slow-release mini-pill includes a drug-containing mini-pill and a coating layer, the drug-containing mini-pill is coated with the coating layer, the drug-containing mini-pill comprises 5mg of tacrolimus, 70mg of a blank pill core, 120-220mg of a filler, 25-125mg of a lubricant and 5-50mg of a binder, the coating layer comprises 35-175mg of Eudragit NE30D and 5-52mg of talc powder, preparation steps of the preparation method are as follows: 1, preparing materials; 2, mixing; 3, preparing the binder; 4, pelleting; 5, preparing a coating agent; 6, coating; 7, filling; and 8, aluminum molding and finishing. The tacrolimus slow-release mini-pill is used for preventing of graft rejection reaction after liver or kidney transplantation and treatment of graft rejection reaction which cannot be controlled by other immunosuppressive drugs after liver or kidney transplantation, and the tacrolimus slow-release mini-pill is more secure, better in stability, and smaller in adverse reactions.

The invention discloses an epigynum auritum pregnane glycoside compound and application thereof in preparation of immunosuppressive drugs. An experiment result shows that the compound has strong activity of suppressing proliferation of splenic lymphocytes. The invention provides a leading compound for research on a new immunosuppressor, and facilitates development and utilization of plant medicinal resources.

A highly specific homogeneous assay method for an immunosuppressive drug using an immunophilin in a single receptor format is provided. In the simplest format, a single receptor is utilized analogous to a competitive immunoassay whereby an immunophilin is substituted for an antibody, and a competition results between a drug conjugate and the drug analyte for a limited number of immunophilin binding sites. In a microparticle agglutination assay format, an immunophilin is either bound to a particle or in solution. In the case where an immunophilin is bound to a particle, a polyvalent conjugate of the drug analyte is present in solution.

The present invention relates to compound of formula I, II, III, or IV, and / or a pharmaceutical acceptable addition salt thereof and / or a stereoisomer thereof and / or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

Novel biological markers indicative of the action of an anti-inflammatory or immunosuppressive drug can be used to evaluate drug efficacy and compare local and systemic drug effects. They can also aid in comparison of different drugs, doses, and delivery routes. The biological markers include cell populations, cell surface antigen expression levels, and soluble factor concentrations. Measurement values of the novel biomarkers were shown to change significantly in allergic, atopic asthmatic, and healthy subjects after administration of prednisone.

A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.